Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Amicus Therapeutics (FOLD) Share Price

Media stories about Amicus Therapeutics (NASDAQ:FOLD) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amicus Therapeutics earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7482306061469 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up $0.01 on Wednesday, reaching $15.17. The company’s stock had a trading volume of 7,937,537 shares, compared to its average volume of 3,710,000. The firm has a market cap of $2,520.00, a P/E ratio of -18.06 and a beta of 1.59. Amicus Therapeutics has a 52-week low of $6.41 and a 52-week high of $17.40. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.60 and a quick ratio of 5.53.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.11). The company had revenue of $14.73 million for the quarter, compared to analyst estimates of $14.50 million. Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. equities research analysts forecast that Amicus Therapeutics will post -1.26 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the company. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Leerink Swann boosted their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, January 15th. Finally, Cowen restated a “buy” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.06.

In other Amicus Therapeutics news, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $13.51, for a total transaction of $885,999.31. Following the transaction, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at approximately $5,310,456.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc bought 335,827 shares of the business’s stock in a transaction on Monday, March 5th. The shares were bought at an average cost of $13.56 per share, for a total transaction of $4,553,814.12. The disclosure for this purchase can be found here. Insiders have sold a total of 207,870 shares of company stock worth $3,066,112 over the last ninety days. Company insiders own 3.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/03/14/amicus-therapeutics-fold-given-media-impact-score-of-0-19/1890457.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.